Research programme: COMT inhibitors - Cerecor

Drug Profile

Research programme: COMT inhibitors - Cerecor

Alternative Names: CERC-406

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Cerecor
  • Class Small molecules
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Depressive disorders

Most Recent Events

  • 23 Mar 2016 Cerecor announces intention to file an IND for CERC 406, with the US FDA (Cerecor, Form 10-K, March 2016)
  • 23 Mar 2016 Cerecor has patent protection for COMT inhibitor compounds in USA (Cerecor, Form 10-K, March 2016)
  • 19 Jan 2016 Preclinical trials in Depressive disorders in USA (PO) (Cerecor pipeline, January 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top